EUVIMEDEUVIMED entdecken
Crossref

Efficacy of meropenem against ceftazidime–avibactam-resistant Klebsiella pneumoniae producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114

Jesus G M Pariona iD, Felipe Vásquez-Ponce iD, Eva M M Pariona iD, Rubens R Sousa-Carmo iD, Thais Martins-Gonçalves iD, Johana Becerra iD, Aline V de Lima iD, Gustavo Queiroga iD, Jorge L M Sampaio iD, Nilton Lincopan iD

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkae389 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Jesus G M Pariona und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Analysis, Faculty of Pharmaceutical Sciences, Universidade de São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: Meropenem, Azabicyclo Compounds, Klebsiella pneumoniae, Ceftazidime. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Conselho Nacional de Desenvolvimento Científico e Tecnológico.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Klebsiella pneumoniae producing KPC variants conferring resistance to ceftazidime–avibactam often remain susceptible to meropenem, suggesting a potential therapeutic use of this antibiotic.

Objectives

In this study, the efficacy of clinically relevant concentrations of meropenem was evaluated against high-risk clones of ceftazidime–avibactam-resistant K. pneumoniae strains producing KPC variants, in a tandem in vitro time-kill/in vivo Galleria mellonella survival model.

Methods

In vitro/in vivo efficacy of meropenem against ceftazidime–avibactam-resistant K. pneumoniae of CG16, CG25 and CG258, producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114 variants, was evaluated using EUCAST dosing recommendation adjusted to the G. mellonella model. For in vivo assays, untreated, meropenem (40 mg/kg × 1)-treated and ceftazidime–avibactam (40 mg/kg ceftazidime–10 mg/kg avibactam × 1)-treated groups were established, with 60 larvae per group. Kaplan–Meier curves, log-rank tests, univariate Cox regression and hazard ratios (HR) were used to assess treatment effects (P < 0.05).

Results

For all KPC-variant producers, time-kill assays showed >3 log-kills reduction (−6.91 ± 1.28 SD) after 6 h interaction when exposed to 8–32 mg/L meropenem MIC values (i.e. ≥ × 4 MIC). In the assessment of in vivo efficacy of meropenem, at the 4-day follow-up, mortality rates were 96.7% (untreated), 83.3% (ceftazidime–avibactam-treated) and 13.3% (meropenem-treated) (P < 0.05). Univariate Cox regression analysis showed significantly lower risk in the meropenem group compared to untreated group [HR 0.02 (95% CI: 0.01–0.05)].

Conclusions

These pre-clinical results might support use of meropenem as a potential alternative for treatment of infections due to KPC-variant producers displaying in vitro susceptibility to meropenem.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeropenemAzabicyclo CompoundsKlebsiella pneumoniaeCeftazidimeAnti-Bacterial AgentsDrug CombinationsKlebsiella Infectionsbeta-LactamasesMicrobial Sensitivity TestsAnimalsDrug Resistance, Multiple, BacterialSurvival Analysis

Substanzen

MeropenemAzabicyclo CompoundsCeftazidimeavibactam, ceftazidime drug combinationAnti-Bacterial AgentsDrug Combinationsbeta-Lactamases

Autor:innen und Institutionen

  • Department of Clinical Analysis, Faculty of Pharmaceutical Sciences, Universidade de São Paulo, São Paulo, Brazil.
  • Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
  • One Health Brazilian Resistance Project (OneBR), São Paulo, Brazil.
  • Unidad de Investigación de Enfermedades Emergentes y Cambio Climático, Universidad Peruana Cayetano Heredia, Lima, Peru.
  • Antimicrobial Resistance Institute of São Paulo (ARIES), São Paulo, Brazil.

ORCID-Profile: Jesus G M Pariona, Felipe Vásquez-Ponce, Eva M M Pariona, Rubens R Sousa-Carmo, Thais Martins-Gonçalves, Johana Becerra, Aline V de Lima, Gustavo Queiroga, Jorge L M Sampaio, Nilton Lincopan

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico

Zitieren

APA

Pariona, J. G. M., Vásquez-Ponce, F., Pariona, E. M. M., Sousa-Carmo, R. R., Martins-Gonçalves, T., Becerra, J., de Lima, A. V., Queiroga, G., Sampaio, J. L. M., & Lincopan, N. (2025). Efficacy of meropenem against ceftazidime–avibactam-resistant Klebsiella pneumoniae producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae389

Vancouver

Pariona JGM, Vásquez-Ponce F, Pariona EMM, Sousa-Carmo RR, Martins-Gonçalves T, Becerra J, et al. Efficacy of meropenem against ceftazidime–avibactam-resistant Klebsiella pneumoniae producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkae389

BibTeX
@article{Pariona2025,
  author = {Pariona, Jesus G M and Vásquez-Ponce, Felipe and Pariona, Eva M M and Sousa-Carmo, Rubens R and Martins-Gonçalves, Thais and Becerra, Johana and de Lima, Aline V and Queiroga, Gustavo and Sampaio, Jorge L M and Lincopan, Nilton},
  title = {Efficacy of meropenem against ceftazidime–avibactam-resistant Klebsiella pneumoniae producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkae389}
}
Kostenlos starten →